US4140753A — Diagnostic method and reagent

Claim 1

Independent Claim 169 words

A radioimmunoassay reagent consisting essentially of the radiolabelled, isolated species of carcinoembryonic antigen denominated CEA-S 1 , said species being characterized by such physicochemical and immunochemical characteristics as: (a) having a single, discrete isoelectric point of about 4.5, as measured by isoelectric columns with ampholytes having a pH range of 3 to 6 or by thin layer pH 3 to 9 acrylamide gels containing ampholytes; (b) having a buoyant density of about 1.41, as measured by isopyknic equilibrium density gradient ultracentrifugation in cesium chloride solution; (c) having a molecular weight of about 181,000 daltons as calculated from the Svedberg equation; (d) precipitating with anti-carcinoembryonic antigen, precipitating preferentially with anti-CEA-S 1 , but not precipitating with antisera to blood group A or B or antisera to normal tissue glycoprotein; (e) having a percent bound antigen vs. antiserum concentration linear regression slope of from about one half to about four fifths the slope of a like curve for carcinoembryonic antigen comparatively tested against identical anti-carcinoembryonic antigen in high ionic strength buffer.

Claim 2

Dependent Claim 169 words

A radioimmunoassay reagent consisting essentially of the radiolabelled, isolated species of carcinoembryonic antigen denominated CEA-S 1 , said species being characterized by such physicochemical and immunochemical characteristics as: (a) having a single, discrete isoelectric point of about 4.5, as measured by isoelectric columns with ampholytes having a pH range of 3 to 6 or by thin layer pH 3 to 9 acrylamide gels containing ampholytes; (b) having a buoyant density of about 1.41, as measured by isopyknic equilibrium density gradient ultracentrifugation in cesium chloride solution; (c) having a molecular weight of about 181,000 daltons as calculated from the Svedberg equation; (d) precipitating with anti-carcinoembryonic antigen, precipitating preferentially with anti-CEA-S 1 , but not precipitating with antisera to blood group A or B or antisera to normal tissue glycoprotein; (e) having a percent bound antigen vs. antiserum concentration linear regression slope of from about one half to about four fifths the slope of a like curve for carcinoembryonic antigen comparatively tested against identical anti-carcinoembryonic antigen in high ionic strength buffer.

Claim 3

Dependent Claim 366 words

The radioimmunoassay reagent consisting essentially of the radiolabelled, isolated tumor-associated antigen denominated CEA-S 1 suitable for use as an aid in the diagnosis of cancer of the human gastrointestinal tract, consisting essentially of the isomer of carcinoembryonic antigen isolated and concentrated from glycoprotein extract of human adenocarcinomas of the intestinal tract being characterized by such physicochemical and immunochemical characteristics as: having a sedimentation velocity of S° 20 ,w = about 6.6 Svedberg units when analyzed by linear sucrose density ultracentrifugation as distinguished from carcinoembryonic antigen having a sedimentation velocity of about 6.8 as determined by the same method; precipitating with antiserum to carcinoembryonic antigen and antiserum to carcinoembryonic antigen isomer in gel double diffusion to give an arc of apparent identity with carcinoembryonic antigen, being preferentially bound by antiserum carcinoembryonic antigen isomer, but not being bound by antisera to blood group A or B or antisera to normal tissue glycoprotein; having a single discrete isoelectric point of about 4.5 measured by isoelectric columns with ampholytes having a pH range of 3 to 6 or by thin layer pH 3 to 9 acrylamide gels containing ampholytes as distinguished from carcinoembryonic antigen isomer which exhibits a distribution of isoelectric points over the range of from about 3 to about 5.2; being indistinguishable from carcinoembryonic antigen when characterized by Sephadex G-200 gel exclusion chromatography; having a buoyant density when isolated from typical colonic adenocarcinomas of about 1.41 when measured by isopyknic equilibrium density gradient ultracentrifugation in cesium chloride solution; and an estimated molecular weight of about 181,000 daltons as calculated from the Svedberg equation M = sRT/D(1 -v ρ ) wherein s is the sedimentation coefficient measured by linear sucrose density ultracentrifugation, D is the diffusion constant as measured by molecular exclusion chromatography on Sephadex G-200 equilibrated with 0.14 M. NaCl, 0.01 sodium phosphate at pH 6.0, v is the partial specific volume estimated as the reciprocal of buoyant density by isopyknic density gradient ultracentrifugation in CsCl, ρ is the density of solution for sedimentation coefficient analysis corrected to 1.00, R is the gas constant and T is the absolute temperature, as distinguished from carcinoembryonic antigen having an estimated molecular weight of about 201,000 measured in the same manner.

Claim 4

Dependent Claim 366 words

The radioimmunoassay reagent consisting essentially of the radiolabelled, isolated tumor-associated antigen denominated CEA-S 1 suitable for use as an aid in the diagnosis of cancer of the human gastrointestinal tract, consisting essentially of the isomer of carcinoembryonic antigen isolated and concentrated from glycoprotein extract of human adenocarcinomas of the intestinal tract being characterized by such physicochemical and immunochemical characteristics as: having a sedimentation velocity of S° 20 ,w = about 6.6 Svedberg units when analyzed by linear sucrose density ultracentrifugation as distinguished from carcinoembryonic antigen having a sedimentation velocity of about 6.8 as determined by the same method; precipitating with antiserum to carcinoembryonic antigen and antiserum to carcinoembryonic antigen isomer in gel double diffusion to give an arc of apparent identity with carcinoembryonic antigen, being preferentially bound by antiserum carcinoembryonic antigen isomer, but not being bound by antisera to blood group A or B or antisera to normal tissue glycoprotein; having a single discrete isoelectric point of about 4.5 measured by isoelectric columns with ampholytes having a pH range of 3 to 6 or by thin layer pH 3 to 9 acrylamide gels containing ampholytes as distinguished from carcinoembryonic antigen isomer which exhibits a distribution of isoelectric points over the range of from about 3 to about 5.2; being indistinguishable from carcinoembryonic antigen when characterized by Sephadex G-200 gel exclusion chromatography; having a buoyant density when isolated from typical colonic adenocarcinomas of about 1.41 when measured by isopyknic equilibrium density gradient ultracentrifugation in cesium chloride solution; and an estimated molecular weight of about 181,000 daltons as calculated from the Svedberg equation M = sRT/D(1 -v ρ ) wherein s is the sedimentation coefficient measured by linear sucrose density ultracentrifugation, D is the diffusion constant as measured by molecular exclusion chromatography on Sephadex G-200 equilibrated with 0.14 M. NaCl, 0.01 sodium phosphate at pH 6.0, v is the partial specific volume estimated as the reciprocal of buoyant density by isopyknic density gradient ultracentrifugation in CsCl, ρ is the density of solution for sedimentation coefficient analysis corrected to 1.00, R is the gas constant and T is the absolute temperature, as distinguished from carcinoembryonic antigen having an estimated molecular weight of about 201,000 measured in the same manner.

Claim 5

Dependent Claim 90 words

The radioimmunoassay reagent consisting essentially of a radiolabelled isolated species of carcinoembryonic antigen denominated CEA-S 1 characterized by: having an antigen binding capacity of anti-CEA for CEA-S 1 significantly greater by at least about 10 percent than the antigen binding capacity for CEA for the same anti-CEA in comparative tests; and having a percent bound antigen vs. antiserum concentration linear regression slope substantially less, from about one half to about four fifths the slope of a like curve for CEA comparatively tested against identical anti-CEA in high ionic strength buffer.

Claim 6

Dependent Claim 90 words

The radioimmunoassay reagent consisting essentially of a radiolabelled isolated species of carcinoembryonic antigen denominated CEA-S 1 characterized by: having an antigen binding capacity of anti-CEA for CEA-S 1 significantly greater by at least about 10 percent than the antigen binding capacity for CEA for the same anti-CEA in comparative tests; and having a percent bound antigen vs. antiserum concentration linear regression slope substantially less, from about one half to about four fifths the slope of a like curve for CEA comparatively tested against identical anti-CEA in high ionic strength buffer.

Claim 7

Independent Claim 136 words

The method of preparing a radioimmunoassay reagent of an isolated species of carcinoembryonic antigen denominated CEA-S 1 comprising the steps of: (a) extracting from adenocarcinomas of the human gastrointestinal tract glycoproteins including carcinoembryonic antigen; (b) isolating from said glycoproteins the carcinoembryonic antigen; (c) isolating from the carcinoembryonic antigen that species which is characterized by having an antigen binding capacity of anti-CEA for CEA-S 1 significantly greater by at least about 10 percent than the antigen binding capacity for CEA for the same anti-CEA in comparative tests, and by having a percent bound antigen vs. antiserum concentration linear regression slope substantially less, from about one half to about four fifths the slope of a like curve for CEA comparatively tested against identical anti-CEA in high ionic strength buffer; and (d) radiolabelling the resulting isolated CEA-S 1 .

Claim 8

Independent Claim 136 words

The method of preparing a radioimmunoassay reagent of an isolated species of carcinoembryonic antigen denominated CEA-S 1 comprising the steps of: (a) extracting from adenocarcinomas of the human gastrointestinal tract glycoproteins including carcinoembryonic antigen; (b) isolating from said glycoproteins the carcinoembryonic antigen; (c) isolating from the carcinoembryonic antigen that species which is characterized by having an antigen binding capacity of anti-CEA for CEA-S 1 significantly greater by at least about 10 percent than the antigen binding capacity for CEA for the same anti-CEA in comparative tests, and by having a percent bound antigen vs. antiserum concentration linear regression slope substantially less, from about one half to about four fifths the slope of a like curve for CEA comparatively tested against identical anti-CEA in high ionic strength buffer; and (d) radiolabelling the resulting isolated CEA-S 1 .

Claim 9

Independent Claim 231 words

The method of preparing a immunoassay reagent of an isolated species of carcinoembryonic antigen denominated CEA-S 1 comprising the steps of: (a) extracting from adenocarcinomas of the human gastrointestinal tract glycoproteins including carcinoembryonic antigen; (b) isolating from said glycoproteins the carcinoembryonic antigen; (c) isolating from the carcinoembryonic antigen that species which is characterized by having an estimated molecular weight of about 181,000 daltons as calculated from the Svedberg equation M = SRT/D(1-vρ ) wherein s is the sedimentation coefficient measured by linear sucrose density ultracentrifugation D is the diffusion constant as measured by molecular exclusion chromatography on Sephadex G-200 equilibrated with 0.14 M. NaCl, 0.01 sodium phosphate at pH 6.0, v is the partial specific volume estimated as the reciprocal of buoyant density by isopyknic density gradient ultracentrifugation in CsCl, ρ is the density of solution for sedimentation coefficient analysis corrected to 1.00, R is the gas constant and T is the absolute temperature, as distinguished from carcinoembryonic antigen having an estimated molecular weight of about 201,000 measured in the same manner, a single discrete isoelectric point of about 4.5 plus or minus 0.1, a sedimentation velocity of about 6.6 Svedberg units and the immunochemical characteristic of precipitating with anti-carcinoembryonic antigen, precipitating preferentially with anti-carcinoembryonic antigen species, but not precipitating with antisera to blood group A or B or antisera to normal tissue glycoprotein, and (d) labelling the resulting CEA-S.sub. 1.

Claim 10

Independent Claim 231 words

The method of preparing a immunoassay reagent of an isolated species of carcinoembryonic antigen denominated CEA-S 1 comprising the steps of: (a) extracting from adenocarcinomas of the human gastrointestinal tract glycoproteins including carcinoembryonic antigen; (b) isolating from said glycoproteins the carcinoembryonic antigen; (c) isolating from the carcinoembryonic antigen that species which is characterized by having an estimated molecular weight of about 181,000 daltons as calculated from the Svedberg equation M = SRT/D(1-vρ ) wherein s is the sedimentation coefficient measured by linear sucrose density ultracentrifugation D is the diffusion constant as measured by molecular exclusion chromatography on Sephadex G-200 equilibrated with 0.14 M. NaCl, 0.01 sodium phosphate at pH 6.0, v is the partial specific volume estimated as the reciprocal of buoyant density by isopyknic density gradient ultracentrifugation in CsCl, ρ is the density of solution for sedimentation coefficient analysis corrected to 1.00, R is the gas constant and T is the absolute temperature, as distinguished from carcinoembryonic antigen having an estimated molecular weight of about 201,000 measured in the same manner, a single discrete isoelectric point of about 4.5 plus or minus 0.1, a sedimentation velocity of about 6.6 Svedberg units and the immunochemical characteristic of precipitating with anti-carcinoembryonic antigen, precipitating preferentially with anti-carcinoembryonic antigen species, but not precipitating with antisera to blood group A or B or antisera to normal tissue glycoprotein, and (d) labelling the resulting CEA-S.sub. 1.

Claim 11

Independent Claim 169 words

The method of preparing an immunoassay reagent of an isolated species of carcinoembryonic antigen denominated CEA-S 1 comprising the steps of: (a) extracting glycoprotein from adenocarcinomas of the human gastrointestinal tract; (b) isolating extracted glycoproteins having a PI of about 4.5 plus or minus 0.1 from the glycoproteins extracted in step (a); (c) isolating from the product of step (b) the glycoproteins having an average molecular weight of about 200,000 daltons as measured by molecular exclusion chromatography on Sephadex G-200 equilibrated with 0.14 M. NaCl, 0.01 sodium phosphate, pH 6.0; (d) fractionating by charge density relative to binding to the ion exchange resin DEAE - cellulose with recovery of the first major peak during elution in 0.05 M Na 2 HPO 4 pH 8. (e) removing from the product of step (c) other proteins, glycoproteins and blood group antigens related molecules by immunoabsorption; (f) isolating from the product of step (d) the glycoprotein having a buoyant density of about 1.41 g/ml; and (g) labelling the resulting CEA-S 1 .

Claim 12

Independent Claim 169 words

The method of preparing an immunoassay reagent of an isolated species of carcinoembryonic antigen denominated CEA-S 1 comprising the steps of: (a) extracting glycoprotein from adenocarcinomas of the human gastrointestinal tract; (b) isolating extracted glycoproteins having a PI of about 4.5 plus or minus 0.1 from the glycoproteins extracted in step (a); (c) isolating from the product of step (b) the glycoproteins having an average molecular weight of about 200,000 daltons as measured by molecular exclusion chromatography on Sephadex G-200 equilibrated with 0.14 M. NaCl, 0.01 sodium phosphate, pH 6.0; (d) fractionating by charge density relative to binding to the ion exchange resin DEAE - cellulose with recovery of the first major peak during elution in 0.05 M Na 2 HPO 4 pH 8. (e) removing from the product of step (c) other proteins, glycoproteins and blood group antigens related molecules by immunoabsorption; (f) isolating from the product of step (d) the glycoprotein having a buoyant density of about 1.41 g/ml; and (g) labelling the resulting CEA-S 1 .

Claim 13

Independent Claim 332 words

The method of preparing an immunoassay reagent of an isolated species of carcinoembryonic antigen denominated CEA-S 1 , comprising the steps of: (a) extracting glycoproteins from adenocarcinomas of the human gastrointestinal tract; (b) isolating by isoelectric focusing of extracted glycoproteins that glycoprotein fraction having an isoelectric point of about 4.5; (c) isolating by molecular exclusion chromatography that fraction of glycoprotein having an isoelectric point of about 4.5 and an average molecular weight of about 200,000 daltons as measured by molecular exclusion chromatography on Sephadex G-200 equilibrated with 0.14 M. NaCl, 0.01 sodium phosphate at pH 6.0; (d) fractionating by charge density relative to binding to the ion exchange resin DEAE - cellulose with recovery of the first major peak during elution in 0.05 M Na 2 HPO 4 pH 8; (e) removing from the fraction of glycoprotein having an isoelectric point of about 4.5 and a molecular weight of about 200,000 daltons by immunoabsorption of proteins, glycoproteins other than carcinoembryonic antigen species, and blood group antigen related molecules; (f) isolating by isopyknic density gradient ultracentrifugation that fraction of glycoproteins which are carcinoembryonic antigen species having an estimated molecular weight of about 181,000 daltons as calculated from the Svedberg equation M = sRT/D(1-vρ ) wherein s is the sedimentation coefficient measured by linear sucrose density ultracentrifugation, D is the diffusion constant as measured by molecular exclusion chromatography on Sephadex G-200 equilibrated with 0.14 M. NaCl, 0.01 sodium phosphate at pH 6.0, v is the partial specific volume estimated as the reciprocal of buoyant density by isopyknic density gradient ultracentrifugation in CsCl, ρ is the density of solution for sedimentation coefficient analysis corrected to 1.00, R is the gas constant and T is the absolute temperature, as distinguished from carcinoembryonic antigen having an estimated molecular weight of about 201,000 measured in the same manner; and an isoelectric point of about 4.5 and being free of other glycoproteins and proteins and blood group antigen related moleculel and (g) labelling the resulting isolated CEA-S 1 .

Claim 14

Independent Claim 332 words

The method of preparing an immunoassay reagent of an isolated species of carcinoembryonic antigen denominated CEA-S 1 , comprising the steps of: (a) extracting glycoproteins from adenocarcinomas of the human gastrointestinal tract; (b) isolating by isoelectric focusing of extracted glycoproteins that glycoprotein fraction having an isoelectric point of about 4.5; (c) isolating by molecular exclusion chromatography that fraction of glycoprotein having an isoelectric point of about 4.5 and an average molecular weight of about 200,000 daltons as measured by molecular exclusion chromatography on Sephadex G-200 equilibrated with 0.14 M. NaCl, 0.01 sodium phosphate at pH 6.0; (d) fractionating by charge density relative to binding to the ion exchange resin DEAE - cellulose with recovery of the first major peak during elution in 0.05 M Na 2 HPO 4 pH 8; (e) removing from the fraction of glycoprotein having an isoelectric point of about 4.5 and a molecular weight of about 200,000 daltons by immunoabsorption of proteins, glycoproteins other than carcinoembryonic antigen species, and blood group antigen related molecules; (f) isolating by isopyknic density gradient ultracentrifugation that fraction of glycoproteins which are carcinoembryonic antigen species having an estimated molecular weight of about 181,000 daltons as calculated from the Svedberg equation M = sRT/D(1-vρ ) wherein s is the sedimentation coefficient measured by linear sucrose density ultracentrifugation, D is the diffusion constant as measured by molecular exclusion chromatography on Sephadex G-200 equilibrated with 0.14 M. NaCl, 0.01 sodium phosphate at pH 6.0, v is the partial specific volume estimated as the reciprocal of buoyant density by isopyknic density gradient ultracentrifugation in CsCl, ρ is the density of solution for sedimentation coefficient analysis corrected to 1.00, R is the gas constant and T is the absolute temperature, as distinguished from carcinoembryonic antigen having an estimated molecular weight of about 201,000 measured in the same manner; and an isoelectric point of about 4.5 and being free of other glycoproteins and proteins and blood group antigen related moleculel and (g) labelling the resulting isolated CEA-S 1 .

Claim 15

Dependent Claim 8 words

The product of the process of claim 7.

Claim 16

Dependent Claim 85 words

In the diagnosis of human gastrointestinal cancer, the improvement in the competitive inhibition immunoassay of carcinoembryonic antigen wherein the immunoassay reagent comprises a labelled isolated species of carcinoembryonic antigen denominated CEA-S 1 and wherein the antigen-antibody reaction is carried out in high ionic strength buffer, to thereby give specificity for antigens resulting from gastrointestinal cancer said labeled isolated species of carcinoembryonic antigen denominated CEA-S 1 characterized by having an antigen binding capacity of anti-CEA for CEA-S 1 significantly greater by at least about 10 percent.

Claim 17

Dependent Claim 85 words

In the diagnosis of human gastrointestinal cancer, the improvement in the competitive inhibition immunoassay of carcinoembryonic antigen wherein the immunoassay reagent comprises a labelled isolated species of carcinoembryonic antigen denominated CEA-S 1 and wherein the antigen-antibody reaction is carried out in high ionic strength buffer, to thereby give specificity for antigens resulting from gastrointestinal cancer said labeled isolated species of carcinoembryonic antigen denominated CEA-S 1 characterized by having an antigen binding capacity of anti-CEA for CEA-S 1 significantly greater by at least about 10 percent.

Claim 18

Dependent Claim 28 words

The improved method of Claim 9 wherein the buffer consists essentially of an aqueous solution of sodium chloride and sodium borate at about pH 7.5 to pH 8.8.

Claim 19

Dependent Claim 24 words

In the radioimmunoassay for CEA, the improved method wherein the radioimmunoassay reagent is a radiolabelled, isolated species of carcinoembryonic antigen denominated CEA-S 1 .

Claim 20

Dependent Claim 24 words

In the radioimmunoassay for CEA, the improved method wherein the radioimmunoassay reagent is a radiolabelled, isolated species of carcinoembryonic antigen denominated CEA-S 1 .

Claim 21

Dependent Claim 43 words

In the radioimmunoassay of CEA, the improved method wherein the radioimmunoassay reagent consists essentially of a species of carcinoembryonic antigen denominated 125 I-CEA-S 1 characterized by having an antigen binding capacity of anti-CEA for CEA-S 1 significantly greater by at least 10 percent.

Claim 22

Dependent Claim 43 words

In the radioimmunoassay of CEA, the improved method wherein the radioimmunoassay reagent consists essentially of a species of carcinoembryonic antigen denominated 125 I-CEA-S 1 characterized by having an antigen binding capacity of anti-CEA for CEA-S 1 significantly greater by at least 10 percent.

Claim 23

Dependent Claim 59 words

The improved competitive inhibition radioimmunoassay method for aiding in the diagnosis of cancer in the gastrointestinal tract of man comprising the use of a radiolabelled isolated species of carcinoembryonic antigen denominated CEA-S 1 as the radioimmunoassay reagent said reagent being characterized by having an antigen binding capacity of anti-CEA for CEA-S 1 significantly greater by at least 10 percent.

Claim 24

Dependent Claim 59 words

The improved competitive inhibition radioimmunoassay method for aiding in the diagnosis of cancer in the gastrointestinal tract of man comprising the use of a radiolabelled isolated species of carcinoembryonic antigen denominated CEA-S 1 as the radioimmunoassay reagent said reagent being characterized by having an antigen binding capacity of anti-CEA for CEA-S 1 significantly greater by at least 10 percent.

Annuity Stage	Window Opens	Payment Deadline	Surcharge Period Until	Estimated Fee	Status
3.5 Years (Year 4)	1982-02-19	1982-08-21	1983-02-20	$2000.00	Window Closed / Lapsed
7.5 Years (Year 8)	1986-02-19	1986-08-21	1987-02-20	$3760.00	Window Closed / Lapsed
11.5 Years (Year 12)	1990-02-19	1990-08-21	1991-02-20	$7700.00	Window Closed / Lapsed

Diagnostic method and reagent

Abstract

Inventors

Bibliographic Details

Claims Analysis

References Cited (Backward Citations)

USPTO Annuity & Maintenance Windows

Assigned Categories & Tags

Assign Category Tag